ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
Efficacy and safety of CT-guided microwave ablation for stage I non-small cell lung cancer in elderly patients.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research status and trend of lung cancer ablation therapy: a bibliometric analysis from 2002 to 2025.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy of MWA for patients aged ≥ 75 years with stage I NSCLC, and to explore the impacts of age and comorbidities on the long-term outcomes.
methodsPatients with stage I NSCLC underwent MWA between November 2016 and December 2020 were retrospectively enrolled. Patients were stratified into two cohorts: ≥ 75 years and < 75 years. Propensity score matching was implemented to control selection bias. Primary endpoints included overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Secondary endpoints included independent risk factors influencing OS.
results138 patients were successfully matched, with 69 in each group. The 1-, 3-, and 5-year OS were 95.7%, 82.6%, and 72.8% in patients aged ≥ 75 years, while 97.1%, 89.9%, and 80.3% in younger patients. There was no significant difference (p = 0.212). The 1-, 3-, and 5-year CSS were 100.0% vs. 98.6%, 92.2% vs. 92.6%, and 83.6% vs. 89.2%, respectively. No significant difference was observed (p = 0.661). The 1-, 3-, and 5-year RFS were 82.1% vs. 88.4%, 60.6% vs. 63.3%, and 58.9% vs. 61.6% without significant difference (p = 0.537). The multivariate COX analysis showed age and Charlson comorbidity index (CCI) were not prognostic factors. Idiopathic pulmonary fibrosis (IPF)/chronic obstructive pulmonary disease (COPD) was an independent risk factor (95% CI 1.32-8.24; p = 0.011).
conclusionMWA is an efficacious tool for patients aged ≥ 75 years with NSCLC. There are no significant differences in efficacy compared with younger patients. Age and CCI are not significant factors associated with prognosis, while IPF/COPD is an independent risk factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.